Compare Quest Diagnostics Inc (DGX) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Jabil Inc — how do they compare? Quest Diagnostics Inc trades at $231.03 (market cap $25.48B), while Jabil Inc trades at $305.46 (market cap $31.35B). The key difference: Jabil Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Jabil Inc for 23 Days on average.
| DGX | JBL | |
|---|---|---|
Market Cap | $25.48B | $31.35B |
Volume | 941,866 | 1,337,978 |
Sector | Health | Technology |
52-Week High | $247.45 | $385.50 |
52-Week Low | $173.49 | $192.49 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $31.23B | $33.63B |
Dividend Yield | 1.49% | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
JBL trades at $301.76, up 0.76% today, with a bearish technical signal despite strong earnings beats in recent quarters. The stock shows robust fundamentals with revenue growth to $29.80B in 2025 and a high ROE of 74.11%, though net margins are thin at 2.9%. AI infrastructure demand is driving optimistic fiscal 2027 guidance, with a consensus analyst price target of $434.75 implying significant upside.
The outlook is positive due to accelerating AI-led growth and strong analyst support, but risks include market volatility post-earnings and high valuation multiples. Investment appeal hinges on execution of projected 24% revenue growth, while current technical weakness may present a buying opportunity for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
